Skip to primary content
Skip to secondary content

Biotech 365

Main menu

  • Biotech 365
  • Companies
  • Healthcare Investors
    • Healthcare LPs
  • Healthcare Investors Matchmaking
  • Free DEMO
  • Services
    • Preclinical Studies Database
    • Scientific Due Diligence
    • CRO & CDMO Database
  • Contact

Tag Archives: Graham Lumsden

Motif Bio – antibiotics against multi-drug resistant bacteria

Posted on by

Motif Bio is a biopharma company specialized in developing novel antibiotics against serious and life-threatening infections caused by multi-drug resistant bacteria.

Motif Bio – antibiotics against multi-drug resistant bacteria

Motif Bio Continue reading →

Posted in Biotech Companies, Biotech Companies UK, Biotech Companies USA | Tagged antibiotic against multi-drug resistant bacteria, antibiotics against multi-drug resistant bacteria, Bruce Williams, Charlotta Ginman, David Huang, DHFR, DHFR inhibitor, dihydrofolate reductase inhibitor, dihydrofolate reductase inhibitors, Graham Lumsden, gram-positive bacteria, hospital‐acquired infection, hospital‐acquired infections, Iclaprim, John Stakes, Jonathan Gold, Mary Lake Polan, methicillin resistant staphylococci, methicillin resistant staphylococcus aureus, methicillin sensitive staphylococci, methicillin‐resistant staphylococcus aureus, Motif Bio, Motif Bio - antibiotics against multi-drug resistant bacteria, MRSA, MSSA, MTF-001, MTF001, multi-drug resistant bacteria, novel antibiotic, novel antibiotics, Richard Morgan, Robert Bertoldi, trimethoprim, Zaki Hosny

        Services              Healthcare Investors Database              FAQs               CGU               Biotech & Pharma News             Contact
Proudly powered by WordPress